127 related articles for article (PubMed ID: 37567175)
21. PTEN Regulates PI(3,4)P
Malek M; Kielkowska A; Chessa T; Anderson KE; Barneda D; Pir P; Nakanishi H; Eguchi S; Koizumi A; Sasaki J; Juvin V; Kiselev VY; Niewczas I; Gray A; Valayer A; Spensberger D; Imbert M; Felisbino S; Habuchi T; Beinke S; Cosulich S; Le Novère N; Sasaki T; Clark J; Hawkins PT; Stephens LR
Mol Cell; 2017 Nov; 68(3):566-580.e10. PubMed ID: 29056325
[TBL] [Abstract][Full Text] [Related]
22. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
[TBL] [Abstract][Full Text] [Related]
23. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Lu Y; Yu Q; Liu JH; Zhang J; Wang H; Koul D; McMurray JS; Fang X; Yung WK; Siminovitch KA; Mills GB
J Biol Chem; 2003 Oct; 278(41):40057-66. PubMed ID: 12869565
[TBL] [Abstract][Full Text] [Related]
24. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
25. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nakahata S; Ichikawa T; Maneesaay P; Saito Y; Nagai K; Tamura T; Manachai N; Yamakawa N; Hamasaki M; Kitabayashi I; Arai Y; Kanai Y; Taki T; Abe T; Kiyonari H; Shimoda K; Ohshima K; Horii A; Shima H; Taniwaki M; Yamaguchi R; Morishita K
Nat Commun; 2014 Feb; 5():3393. PubMed ID: 24569712
[TBL] [Abstract][Full Text] [Related]
26. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.
Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D
Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571
[TBL] [Abstract][Full Text] [Related]
27. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
28. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
[TBL] [Abstract][Full Text] [Related]
29. PTEN inhibits BMI1 function independently of its phosphatase activity.
Fan C; He L; Kapoor A; Rybak AP; De Melo J; Cutz JC; Tang D
Mol Cancer; 2009 Nov; 8():98. PubMed ID: 19903340
[TBL] [Abstract][Full Text] [Related]
30. PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate.
Wise HM; Harris A; Kriplani N; Schofield A; Caldwell H; Arends MJ; Overton IM; Leslie NR
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291720
[TBL] [Abstract][Full Text] [Related]
31. Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression.
Guo Y; He J; Zhang H; Chen R; Li L; Liu X; Huang C; Qiang Z; Zhou Z; Wang Y; Huang J; Zhao X; Zheng J; Chen GQ; Yu J
Oncogene; 2022 Oct; 41(44):4877-4892. PubMed ID: 36192478
[TBL] [Abstract][Full Text] [Related]
32. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY
Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414
[TBL] [Abstract][Full Text] [Related]
33. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
34. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
[TBL] [Abstract][Full Text] [Related]
35. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Lee SH; Poulogiannis G; Pyne S; Jia S; Zou L; Signoretti S; Loda M; Cantley LC; Roberts TM
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11002-7. PubMed ID: 20534477
[TBL] [Abstract][Full Text] [Related]
36. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
Miller KA; Degan S; Wang Y; Cohen J; Ku SY; Goodrich DW; Gelman IH
Oncogene; 2024 Jan; 43(1):22-34. PubMed ID: 37875657
[TBL] [Abstract][Full Text] [Related]
37. Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway.
Liu GL; Yang HJ; Liu B; Liu T
J Cell Biochem; 2017 Oct; 118(10):3424-3434. PubMed ID: 28322459
[TBL] [Abstract][Full Text] [Related]
38. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
39. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
40. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
